RISK FACTORS FOR DEVELOPMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS AMONG RELAPSED PATIENTS IN WEST PAPUA, INDONESIA: A DESCRIPTIVE AND ANALYTICAL STUDY
Objective: Indonesia has one of the highest burdens of multidrug-resistant tuberculosis (MDR-TB), with 6800 new cases of MDR-TB annually and a previously reported cure rate of 51%. This study aimed to identify the risk factors that affect the development of MDR-TB in the diverse population of West Papua.
Methods: A case–control study was conducted in Sorong Regency Regional Hospital, a referral center for MDR-TB in West Papua. Data were obtained from medical records of patients with relapsed TB between January 2014 and September 2017. Extracted data included demographic characteristics, family history, medication history (type of medication and duration), smoking history, supporting examinations (sputum test for acid-fast bacilli [AFB] and radiologist interpretation of thoracic X-ray), and comorbidities (HIV and diabetes mellitus).
Results: Among 549 patients with suspected MDR-TB, 45 were confirmed to have MDR-TB. These 45 patients were defined as the case group and compared with a control group of 45 relapsed patients who had drug-sensitive TB. A great number of subjects in both case and control groups (44.4% and 57.8%) were categorized as previously lost to follow-up. Bivariate analysis using the chi-squared test found that an AFB result of+3 (odds ratio [OR]: 5.33, 95% confidence interval [CI] 1.76–16.09), diabetes mellitus (OR: 6.14, 95% CI 1.26–29.89), and completion of intensive-phase category I anti-TB therapy (OR: 3.25, 95% CI 1.04–10.07) were associated with MDR-TB.
Conclusion: These clinical variables provide initial information about MDR-TB in West Papua and will assist clinicians to manage patients in related populations who have these risk factors.
2. WHO Indonesia Tuberculosis Profile; 2017. Available from: https://extranet.who.int/sree/Reports?op=Repletandname=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfileandISO2=IDandLAN=ENandouttype=pdf [Last accessed on 18 Oct 2018]
3. USAID. Indonesia MDR-TB country profile; 2016. Available from: https://www.usaid.gov/sites/default/files/documents/1864/Indonesia_MDR-TB_508_ck.pdf [Last accessed on 18 Oct 2018]
4. WHO. Multidrug resistant tuberculosis (MDR-TB); 2017. Available from: http://www.who.int/tb/challenges/mdr/MDR-RR_TB_factsheet_2017.pdf [Last accessed on 18 Oct 2018]
5. Magee MJ, Kempker RR, Kipiani M. Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia. PLoS ONE 2014;9:1–9.
6. Barroso EC, Mota RMS, Santos RO, Sousa ALO, Barroso JB, Rodrigues JLN. Risk factors for acquired multidrug-resistant tuberculosis. J Pneumol 2003;29:89–97.
7. Rifat M, Milton AH, Hall J. Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors. PLoS ONE 2014;9:2–8.
8. Chuchottaworn C, Thanachartwet V, Sangsayunh P. Risk factors for multidrug-resistant tuberculosis among patients with pulmonary tuberculosis at the central chest institute of Thailand. PLoS ONE 2015;10:1–17.
9. Swaminathan S, Paramasivan CN, Ponnuraja C, Iliayas S, Rajasekaran S, Narayanan PR. Anti-tuberculosis drug resistance in patients with HIV and tuberculosis in South India. Int J Tuberc Lung Dis 2005;9:896–900.
10. Liu Q, Li W, Xue M. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep 2017;7:1–7.
11. Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci 2015;15:368–77.
12. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006;61:158–63.
13. Casal M, Vaquero M, Rinder H. A case-control study for multidrug-resistant tuberculosis: Risk factors in four European countries. Microb Drug Resist 2005;11:62–7.
14. Raazi J, Prakash S, Parveen K, Shaikh S. Risk factors of multi-drug resistant tuberculosis in urban Allahabad, India. Int J Community Med Public Health 2017;4:2383–8.
15. Hirpa S, Medhin G, Girma B. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in addis ababa: a case control study. BMC Public Health 2013;13:1.
16. Cox HS, Niemann S, Ismailov G. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis 2007;44:1421–7.
17. Castelnuovo B. A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa. Afr Health Sci 2010;10:320–4.
18. Stosic M, Vukocic D, Babic D, Antonijevic G, Foley KL, Vujcic I, et al. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study. BMC Public Health 2018;18:1114.
19. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012;55:169–77.
20. Caetano Mota P, Carvalho A, Valente I, Braga R, Duarte R. Predictors of delayed sputum smear and culture conversion among a portuguese population with pulmonary tuberculosis. Rev Port Pneumol 2012;18:72–9.
21. Djouma FN, Noubom M, Ateudjieu J, Donfack H. Delay in sputum smear conversion and outcomes of smear-positive tuberculosis patients: a retrospective cohort study in Bafoussam, Cameroon. BMC Infect Dis 2015;15:1–7.
This work is licensed under a Creative Commons Attribution 4.0 International License.